Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical radioimmunotherapy.

S J Knox1, R F Meredith

  • 1Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA.

Seminars in Radiation Oncology
|March 23, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.

Journal of viral hepatitis·2016
Same author

Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong.

Alimentary pharmacology & therapeutics·2015
Same author

Impaired bioavailability of interferon beta-1a when administered intramuscularly by needle-free injection.

Drug delivery·2009
Same author

Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells.

The Prostate·2005
Same author

The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy.

Apoptosis : an international journal on programmed cell death·2003
Same author

Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line.

Cell death and differentiation·2002
Same journal

Integrative Medicine for Breast Cancer Survivors.

Seminars in radiation oncology·2026
Same journal

Integrative Oncology Approaches for Gastrointestinal Symptoms and Risk Reduction in Patients With Digestive Tract Cancers.

Seminars in radiation oncology·2026
Same journal

Integrative Oncology and Radiation Therapy: An Essential Evolution.

Seminars in radiation oncology·2026
Same journal

Clinical Trials of Integrative Oncology Interventions for Radiation Therapy: Emerging Evidence and Opportunities.

Seminars in radiation oncology·2026
Same journal

Nonpharmacologic Approaches for Pain Management in Patients With Cancer Treated With Radiation Therapy.

Seminars in radiation oncology·2026
Same journal

Integrative Therapies for Radiation-Related Toxicities in Hematological Malignancies.

Seminars in radiation oncology·2026
See all related articles

Radioimmunotherapy (RIT) shows promise for treating various cancers, particularly blood cancers. Clinical trials demonstrate high response rates and durable remissions with RIT, which is generally well-tolerated.

Area of Science:

  • Oncology
  • Immunotherapy
  • Nuclear Medicine

Background:

  • Radioimmunotherapy (RIT) is an emerging therapeutic modality for diverse malignancies.
  • Key considerations for RIT include the selection of appropriate monoclonal antibodies (MAb) and radionuclides.
  • RIT combines the specificity of antibodies with the cytotoxic effects of radiation for targeted cancer treatment.

Purpose of the Study:

  • To discuss the general principles of Radioimmunotherapy (RIT).
  • To summarize the results of clinical trials investigating RIT for various cancers.
  • To review approaches for enhancing the therapeutic index of RIT.

Main Methods:

  • Review of general principles of Radioimmunotherapy (RIT).
  • Analysis of clinical trial data for RIT in lymphoma, leukemia, and solid tumors.

Related Experiment Videos

  • Examination of toxicity profiles and therapeutic index enhancement strategies for RIT.

    • Main Results:

    • RIT demonstrates promising results, especially for lymphohematopoietic malignancies, achieving high and durable response rates.
    • Encouraging outcomes are also observed in solid tumors, particularly in patients with low tumor burden.
    • The primary toxicity associated with RIT is transient myelosuppression; nonhematologic toxicity is minimal at nonmyeloablative doses.

    Conclusions:

    • Radioimmunotherapy (RIT) is a viable and effective treatment option for several cancers.
    • RIT exhibits a favorable safety profile, with manageable side effects.
    • Further optimization of RIT strategies can potentially improve efficacy and reduce toxicity.